The IL-12Rβ2 gene functions as a tumor suppressor in human B cell malignancies
J. Clin. Invest. Irma Airoldi, et al. 113:1651 doi:10.1172/JCI20303 [Go to this article.]

Figure 1
Expression of IL-12R in human tonsil B cells. (A) Expression of IL-12Rβ1 and IL-12Rβ2 mRNA in tonsil B cells and their subsets. From left to right: molecular weight markers (MW); negative control (NC, represented by a Th2 cell clone for CD56, CD19, and IL-12Rβ2 primers; purified tonsil B cells for CD3γ primers; or water in the place of cDNA for IL12Rβ1 and GAPDH primers); positive control (PC, represented by a Th1 cell clone for CD3γ, IL12Rβ1, and IL-12Rβ2 primers; tonsil non_T cells for CD56 primers; or the RPMI 8866 B cell line for CD19 primers). The remaining lanes represent total tonsil B lymphocytes and naive, GC, and memory B cells, respectively, isolated from the same tonsil. On the right, the expected molecular weight of the amplified bands are shown. (B_N) Expression of IL-12Rβ2 protein in frozen tonsil tissue sections. (B) FM, GC, and SE, are boxed (magnification, ∞20). FM staining with CD19 mAb (C, green), anti_IL-12Rβ2 mAb (D, red), and both mAb's in combination with DAPI (E); in E, overlap of green and red colors gives rise to yellow staining, indicating that most cells coexpress CD19 and IL-12Rβ2; control FM staining with DAPI and with isotype- and fluorochrome-matched mAb's of irrelevant specificity (F). Staining of SEs (G_J) and GC areas (K_N) are shown in the same order as FM. Magnification (C_N), ∞100 for all panels.